A cost sensitivity analysis was performed for an industrial membrane bioreactor to quantify the effects of hydraulic retention times and related operational parameters on cost. Different hydraulic retention times (72–24 h) were subjected to a flat-sheet membrane bioreactor updated from an existing 72 h oxidation ditch treating antibiotic production wastewa ter. Field experimental data from the membrane bioreactor, both full-scale (500 m³/d) and pilot (1.0 m³/d), were used to calculate the net present value (NPV), incorporating both capital expenditure (CAPEX) and operating expenditure. The results showed that the tank cost was estimated above membrane cost in the 38.2%, where capital expenditure contributed 24.2% more than operational expenditure. Tank construction cost was decisive in determining the net present value contributed 62.1% to the capital expenditure. The membrane bioreactor has the advantage of a longer lifespan flat-sheet membrane, while flux decline was tolerable. The antibiotics decreased to 1.87±0.33 mg/L in the MBR effluent. The upgrade to the membrane bioreactor also benefited further treatments by 10.1%–44.7% lower direct investment.

对工业膜生物反应器进行了成本敏感性分析，以量化水力停留时间和相关操作参数对成本的影响。不同的水力停留时间（72-24小时）要经过一个平板膜生物反应器，该反应器是根据现有的72小时氧化沟处理抗生素生产废水而更新的。来自膜生物反应器的现场实验数据，满量程（500 m ³ / d）和中试（1.0 m ^3）/ d）来计算净现值（NPV），包括资本支出（CAPEX）和运营支出。结果表明，储罐成本估计高于膜成本，为38.2％，其中资本支出比运营支出贡献了24.2％。储罐建造成本对确定净现值占资本支出的62.1％起着决定性作用。膜生物反应器的优点是使用寿命更长的平板膜，而通量下降是可以容忍的。MBR流出物中的抗生素降至1.87±0.33 mg / L。膜生物反应器的升级还使进一步处理受益，直接投资减少了10.1％至44.7％。